Cholangiocarcinoma Foundation Launches Trusted Partners Program

FDA Approves Incyte’s Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma

Cholangiocarcinoma Foundation (CCF) partners with organizations worldwide to achieve its mission: find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). Collaboration is a core value at CCF and is fundamental to the Foundation’s growth and ability to provide high-quality programs and services to the CCA community.

CCF engages in a diversity of partnerships that include other nonprofit organizations, for-profit companies, healthcare institutions, and others. The increasing instances of CCA and the expanding field compelled CCF to create a trusted partner program to identify organizations that they work closely within the oncology and CCA space. These partners share an alignment of core values, have a long-term, trusting relationship, complementary strengths, and share a passion for our collaborative work.

“The science has matured a lot in CCA, and as CCF has grown, so have our partnerships. Collaborating with partners is crucial to CCF’s mission. Partnerships are at the heart of the way we work. The relationships we build with our partners allow us to leverage resources, extend our reach in all aspects, and widen our work’s impact. It is important for us to know that our partners have shared values, among other important factors. We are very grateful for the excellent work our partners have helped accomplish for this community,” said Stacie Lindsey, CCF Founder, and CEO.

CCF’s current trusted partners are Ciitizen, Komodo Health, The Lynx Group, and D2 Creative.

Ciitizen: CCF partnered with Ciitizen to enable easier access to patient health records. Ciitizen is a consumer health tech company building a platform that helps patients collect, organize, and share their medical records digitally. The records are converted into a digital and actionable health profile shareable with doctors, family members, and researchers. For the last year and a half, Ciitizen and CCF have partnered to enable CCA patients to harness the power of their health data for their own care and to power research. Together, we have launched comprehensive Clinical Trial Matching and supported multiple patient-driven research studies.

“It’s a privilege to be a Trusted Partner of CCF. Stacie and her team work tirelessly to improve the day-to-day quality of life for those affected by cholangiocarcinoma while also cultivating the creative and innovative thinking necessary to accelerate cures,” added Farid Vij, Co-Founder at Ciitizen.

“CCF’s commitment to their patients and community is unmatched. We are proud to further the mission of CCF together through our partnership,” said Anil Sethi, Founder & CEO of Ciitizen.

D2 Creative: D2 Creative delivers engaging creative campaigns using unique and powerful storytelling techniques that change hearts, minds, and ultimately behavior. D2 Creative has helped CCF produce several patient-friendly videos explaining important topics about cholangiocarcinoma. The growing collection contains Mutations Matter, Understanding your Clinical Trials, Biomarkers Matter, and Learning About Clinical Trials.

“D2 Creative is honored to support the important work and mission of CCF in our own small way, leveraging the power of storytelling to help patients understand complex and sometimes scary science in an accessible and easy-to-understand format,” said Laura Vitez O’Donnell, Director of Content and Storytelling.

Komodo Health: Partnering with Komodo Health has helped CCA patients get better access to providers and specialists around the country by leveraging their unique intelligence platform, which combines de-identified data from over 500 sources capturing more than 320 million Americans’ healthcare journey. With this data, we can connect patients with the best care possible through the CCA specialist map. Komodo Health makes it possible for patients to find the nearest specialist with the most expertise in treating CCA with the click of a button.

“Organizations like CCF serve as a constant reminder of our mission to reduce the burden of disease,” said Aswin Chandrakantan, MD, chief medical officer at Komodo Health. “When you’re fighting cancer, it’s always a race, and we are honored that our software has helped connect patients with the right specialists so they can find the best treatment path faster.”

The Lynx Group: One of CCF’s core values is patients first in everything we do. The Lynx Group helps CCF reach this goal by improving patients’ and caregivers’ lives through their partnerships with key healthcare stakeholders. The Lynx Group is a global strategic medical communications and education company. They strive to provide pivotal and contemporary information and education for all stakeholders in healthcare. CCF partners with Lynx on the Cholangiocarcinoma Summit and the publications CCA News and CONQUERING Cholangiocarcinoma.

“It is a great honor to be named a trusted partner of the CCF. We have been collaborating with this stellar team for the last three years and have developed several programs and resources that have a direct impact on the care that patients with cholangiocarcinoma receive. There are a lot of
promising treatments in the pipeline for patients with cholangiocarcinoma and our partnership with the CCF will help communicate advances to all cancer care stakeholders with the goal of optimizing patient care,” said Nick Englezos, Executive Vice President at The Lynx Group.

For more information about CCF’s trusted partners, please visit our Trusted Partners’ Page.

– Stacie Lindsey
CCF Founder, and CEO